

2017 Educational Session Content References

General Session I: Screening, Diagnosis and Staging

Lung Cancer Screening

1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011;365(5):395-409.
2. Wood DE. The importance of lung cancer screening with low-dose computed tomography for Medicare beneficiaries. *JAMA Intern Med*. 2014;174(12):2016-2018.
3. Wood DE, Kazerooni E, Baum SL, et al. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2015;13(1):23-34.

Is the Nodule Malignant?

1. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5)(suppl):eS93-eS120. doi: 10.1378/chest.12-2351.
2. Tanner NT, Aggarwal J, Gould MK, et al. Management of pulmonary nodules by community pulmonologists: A multicenter observational study. *Chest*. 2015;148(6):1405-1414.
3. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot? A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. *Chest*. 2013;143(3):672-677.

Mediastinal Staging Approaches: Minimally Invasive to Invasive

1. Vilman P, Frost PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Eur J Cardiothorac Surg*. 2015;48(1):1-15.
2. De Leyn P, Doooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer. *Eur J of Cardiothorac Surg*. 2014;45(5):787-798.
3. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5)(suppl):eS211-S250. doi: 10.1378/chest.12-2355.

Keynote I: Personalized Surgical Approaches to Therapy

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*. 2011;6(2):244-285.
2. Kadota K, Nitadori J, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. *J Thorac Oncol*. 2015;10(5):806-814.
3. Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less be more? A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. *Lung Cancer*. 2015;89(2):121-132.

General Session II: Early Stage Thoracic Cancers

1. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev*. 2015;(3): CD011430. doi: 10.1002/14651858.CD011430.
2. Oh SY, Kim MY, Kim JE, et al. Evolving early lung cancers detected during follow-up of idiopathic interstitial pneumonia: serial CT features. *AJR Am J Roentgenol*. 2015;204(6): 1190-1196. doi: 10.2214/AJR.14.13587.
3. Makey I, Berger RL, Cabral HJ, et al. Maximal oxygen uptake--risk predictor of NSCLC resection in patients with comorbid emphysema: lessons from NETT. *Semin Thorac Cardiovasc Surg*. 2015;27(2):225-231. doi: 10.1053/j.semtcv.2015.07.009.
4. Pisters KW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stage I-IIIa resectable non-small cell lung cancer guideline. *J Clin Oncol*. 2007;25(34):5506-5518.

General Session III: Locally Advanced Stage III Cancer

1. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016: *J Natl Compr Canc Netw*. 2016;14(3):255-64. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
2. Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. *J Clin Oncol*. 2015;33(18):196-197.

General Session IV: Practical Guidance in Precision Medicine – Bridging the Gap Between Research and the Clinic

1. Garofalo A, Sholl L, Reardon B, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. *Genome Med*. 2016;8(1):79. doi: 10.1186/s13073-016-0333-9.
2. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. *Nat Rev Cancer*. 2016;16(8):525-537.

General Session V: Advanced Non-small Cell Lung Cancer, Part I - Targeted Therapy and Immunotherapy

Targeted Therapy and Management of Acquired Drug Resistance

1. Jänne PA, Yang Jc, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer. *N Engl J Med*. 2015;372(18):1689-1699.
2. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small cell lung cancer. *N Engl J Med*. 2014;370(13):1189-1197.
3. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol*. 2016;17(2):234-242.

Immunotherapy: How to Apply in Practice, Choosing Patients and Management of Side Effects

1. Brahmer J, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. *N Engl J Med*. 2015;373(2):123-135.
2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. *N Engl J Med*. 2015;373(17):1627-1639
3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.

Immunotherapy: Management of Early and Delayed Progression

1. Jänne PA, Yang Jc, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer. *N Engl J Med*. 2015;372(18):1689-1699.
2. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol*. 2016;17(2):234-242.
3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.

General Session V: Advanced Non-small Cell Lung Cancer, Part II

Oligometastatic Disease

1. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. *Lancet Oncol*. 2013;14(1):e28-e37. doi: 10.1016/S1470-2045(12)70510-7.
2. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet*. 2004;363(9422): 1665-1672.

Palliative Care for Lung Cancer

1. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol*. 2007;25(11):1423-1436.

Quality of Life

1. Movsas B, Hu C, Sloan J, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small cell lung Cancer: A secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. *JAMA Oncol*. 2016;2(3):359-367.
2. Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. *J Clin Oncol*. 2014;32(26):2920-2927.

General Session VI: Other Thoracic Tumors

Small Cell Lung Cancer

1. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. *J Clin Oncol*. 2009;27(1):78-84.
2. Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive stage small-cell lung cancer—Authors' reply. *Lancet*. 2015;385(9975):1292-1293.
3. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;17(7):883-895.
4. Schneider J, Kalemkerian G. Personalized therapy of small cell lung cancer. In: Ahmad A, Gadgeel SM, eds. *Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management*. Berlin, Germany: Springer; 2016. *Advances in Experimental Medicine and Biology*; vol 890.

Mesothelioma

1. Friedberg, JS. The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma. *Semin Thorac Cardiovasc Surg*. 2013;25(2):125-143. doi: 10.1053/j.semtcvs.2013.07.002.
2. Friedberg JS, Culligan MJ, Mick R, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. *Ann Thorac Surg*. 2012;93(5):1658-1667.
3. Pass H, Rice D, Wolf A, Friedberg J, Vigneswaran W. The next generation of mesothelioma surgeons roundtable discussion. *Semin Thorac Cardiovasc Surg*. 2016;28(1):203-220.

Thymic Tumors

1. Rimner A, Yao X, Huang J, et al. Postoperative radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma—an analysis of the International Thymic Malignancies Interest Group retrospective database. *J Thorac Oncol*. 2016;11(10):1785-1792.
2. Boothe D, Orton A, Thorpe C, Kokeny K, Hitchcock Y. Postoperative radiotherapy in locally invasive malignancies of the thymus: Patterns of care and survival. *J Thorac Oncol*. 2016;11(12):2218-2226.
3. Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg*. 2016;151(1):47-57.

Keynote III: Immunotherapeutic Strategies for Management of Lung Cancer

1. Brahmer J, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. *N Engl J Med*. 2015;373(2):123-135.
2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. *N Engl J Med*. 2015;373(17):1627-1639
2. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.

General Session VII: Immunotherapy in Lung Cancer

1. Porter ME. What is value in health care? *N Engl J Med*. 2010;363(26):2477-2481.
2. Twyman-Saint VC, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015;520(7547):373-377.
3. Dammeyer F, Lievens LA, Veerman GD, et al. Efficacy of tumor vaccines and cellular immunotherapies in non-small cell lung cancer: A systematic review and meta-analysis. *J Clin Oncol*. 2016;34(26):3204-3212.